Nucor earnings beat by $0.08, revenue fell short of estimates
MINNEAPOLIS—On February 25, 2025, Daniel L. Reuvers, a director at Tactile Systems Technology Inc . (NASDAQ:TCMD), executed a notable stock transaction involving the sale of 28,338 shares of the company’s common stock. The shares were sold at a weighted average price of $14.18, with sale prices ranging from $14.09 to $14.49 per share, totaling approximately $401,849. The medical device company, currently valued at $336 million, maintains strong financial health with a "GREAT" rating according to InvestingPro metrics.
Following this transaction, Reuvers retains ownership of 214,604 shares in the company. The sale was conducted under a pre-established 10b5-1 trading plan, which was adopted on June 10, 2024. The shares sold were intended to cover taxes associated with the settlement of stock units. The transaction comes as TCMD’s stock has declined 15.24% year-to-date, though the company maintains robust fundamentals with a healthy current ratio of 4.36.
This transaction highlights a strategic financial move by Reuvers, reflecting his ongoing engagement with Tactile Systems Technology. According to InvestingPro analysis, the stock appears undervalued at current levels, with multiple positive indicators including strong cash flows and profitability. Discover more insights and access the comprehensive Pro Research Report, along with 8 additional ProTips, available exclusively on InvestingPro.
In other recent news, Tactile Systems Technology reported a strong financial performance for the fourth quarter of 2024. The company exceeded earnings expectations with an earnings per share (EPS) of $0.40, surpassing the forecast of $0.31. Revenue for the quarter reached $85.6 million, slightly above the anticipated $85.41 million, marking a year-over-year growth of 10.2%. Despite these positive results, B.Riley analysts downgraded Tactile Systems from Buy to Neutral, adjusting the price target from $23 to $18. Concerns were raised due to slowing earnings growth and ongoing legal challenges, including qui tam lawsuits. Tactile Systems’ guidance for fiscal year 2025 projects revenue between $316 million and $322 million, with adjusted EBITDA expected to range from $35 million to $37 million. This EBITDA guidance fell short of the consensus estimate of $45.2 million. The company’s focus remains on expanding its product lines and improving patient access, as emphasized during their earnings call.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.